drugset / Trial / NCT02476058

A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder

NCT02476058

Phase 1 Completed 48 enrolled Janssen-Cilag International NV
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of JNJ-42847922 in participants with Major Depressive Disorder (MDD).

Timeline

Start
2015-06-11
Primary completion
2016-01-04
Completion
2016-01-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Diphenhydramine Unknown 25 mg Oral
Subject Seltorexant Small molecule 20 mg Oral